Globus Medical, Inc. (GMED)
| Market Cap | 6.25B |
| Revenue (ttm) | 789.04M |
| Net Income (ttm) | 102.29M |
| Shares Out | 98.58M |
| EPS (ttm) | 1.01 |
| PE Ratio | 62.06 |
| Forward PE | 34.13 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $62.68 |
| Previous Close | $62.50 |
| Change ($) | 0.18 |
| Change (%) | 0.29% |
| Day's Open | 63.26 |
| Day's Range | 62.44 - 63.95 |
| Day's Volume | 571,066 |
| 52-Week Range | 33.41 - 68.24 |
Globus Medical's (GMED) spinal implant business performance varies by region in Q4.
Globus Medical (GMED) delivered earnings and revenue surprises of 13.73% and -0.34%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Globus Medical (NYSE:GMED) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 18.37% over the past year to $0.58, which ...
AUDUBON, Pa., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and...
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUDUBON, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and fu...
Globus Medical's (GMED) recent product launches are seeing tremendous uptake.
Globus Medical (GMED) saw a visible rebound in its revenue trend in the third quarter.
Globus Medical: Entry At The Pullback Paid Off, Upside On Entry Today Equally Exciting
AUDUBON, Pa., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, was recently awarded a group purchasing agreement with Premier, o...
Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement in the third quarter.
Globus Medical (GMED) is optimistic about maintaining robust product portfolio along with strength in its domestic spine business.
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?
New ExcelsiusGPS® Interbody Solutions module expands system for planning and navigating the entire interbody fusion procedure New ExcelsiusGPS® Interbody Solutions module expands system for pl...
Globus Medical's (GMED) spinal implant business performance varies by region in Q3.
Globus Medical, Inc. (GMED) CEO Dave Demski on Q3 2020 Results - Earnings Call Transcript
Globus Medical (GMED) delivered earnings and revenue surprises of 58.06% and 9.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AUDUBON, Pa., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended Sept...
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUDUBON, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended S...
Globus Medical Has Reached The 10% Pullback We Were Hoping For - Time For Entry
Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.
AUDUBON, Pa., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced it will participate as a platinum sponsor at the ...
Robotics stocks offer great opportunities for growth investors and recent adoptions have accelerated the industry's growth rapidly.
A Relative Strength Rating upgrade for Globus Medical shows improving technical performance. Will it continue?
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?
Globus Medical is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.
Globus Medical Climbs 18.12% From Q2 Exit - Beats EPS By $0.18; But Let's Not Jump In Just Yet
Globus Medical (GMED) witnesses dismal segmental and international performance in the second quarter owing to pandemic-led adversities.
The medical device maker reported second-quarter results that were much better than expected.
Globus Medical, Inc. (GMED) CEO Dave Demski on Q2 2020 Results - Earnings Call Transcript
Globus Medical (GMED) delivered earnings and revenue surprises of 163.64% and 49.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AUDUBON, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the second quarter e...
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health care is supposed to be a very defensive sector in investing. After all, diseases and conditions such as cancer, diabetes, heart disease, kidney failure, dementia, joint damage and spina...
AUDUBON, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended...
Big data is becoming a big factor in the healthcare industry.
Robotics stocks offer multi-decade growth potential. These 10 stocks offer some of the best exposure to this attractive trend.
Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.
Globus Medical, Inc. (GMED) CEO Dave Demski on Q1 2020 Results - Earnings Call Transcript
Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.
The medical-device maker's revenue and earnings fell below Wall Street expectations.
Globus Medical (GMED) delivered earnings and revenue surprises of -27.50% and -4.65%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare stocks are in the spotlight as the coronavirus brings to light the importance of collecting data and using it to predict outcomes.
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?
Globus Medical Inc’s (NYSE: GMED) shares have declined around 33% from their year-end 2019 high, and the company has a strong balance sheet that can be used to acquire assets at depressed valu...
AUDUBON, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the Board of Directors authorized the repurcha...
Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.
About GMED
Globus Medical, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pa... [Read more...]
| Industry Medical Devices | IPO Date Aug 3, 2012 |
| CEO David Demski | Employees 2,200 |
| Stock Exchange NYSE | Ticker Symbol GMED |
Financial Performance
In 2020, Globus Medical's revenue was $789.04 million, an increase of 0.47% compared to the previous year's $785.37 million. Earnings were $102.29 million, a decrease of -34.10%.
Analyst Forecasts
According to 16 analysts, the average rating for Globus Medical stock is "Buy." The 12-month stock price forecast is 71.47, which is an increase of 14.02% from the latest price.